SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
Retrieved on:
Lunedì, Aprile 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry
Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
Key Points:
- Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
- Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
- Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
- SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.